At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LIPO Lipella Pharmaceuticals Inc
Closed 05-15 16:00:00 EDT
0.7632
+0.0132
+1.76%
盘后0.7550
-0.0082-1.07%
19:49 EDT
High0.7638Low0.7500Vol15.87K
Open0.7500D1 Closing0.7500Amplitude1.84%
Mkt Cap5.80MTradable Cap3.67MTotal Shares7.61M
T/O11.98KT/O Rate0.33%Tradable Shares4.81M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Lipella Pharmaceuticals First Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.19 loss in 1Q 2023)
Simply Wall St.  ·  05-13 19:09
Lipella Pharmaceuticals First Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.19 loss in 1Q 2023)
BRIEF-Lipella Pharmaceuticals Expands Its Advisory Board To Include Oncology Expertise
Reuters  ·  04-17
BRIEF-Lipella Pharmaceuticals Expands Its Advisory Board To Include Oncology Expertise
Press Release: Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
Dow Jones  ·  04-17
Press Release: Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
GlobeNewswire  ·  04-05
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
BRIEF-Lipella Pharmaceuticals Announces FDA Type C Meeting For LP-10 For Hemorrhagic Cystitis
Reuters  ·  04-03
BRIEF-Lipella Pharmaceuticals Announces FDA Type C Meeting For LP-10 For Hemorrhagic Cystitis
Lipella announces FDA type C meeting for its hemorrhagic cystitis treatment
seekingalpha  ·  04-03
Lipella announces FDA type C meeting for its hemorrhagic cystitis treatment
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease
GlobeNewswire  ·  03-08
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease
BRIEF-Lipella Pharmaceuticals Announces US FDA Clearance Of IND For LP-410 For Oral Graft-Versus-Host Disease
Reuters  ·  03-05
BRIEF-Lipella Pharmaceuticals Announces US FDA Clearance Of IND For LP-410 For Oral Graft-Versus-Host Disease
Lipella Pharmaceuticals Full Year 2023 Earnings: US$0.77 loss per share (vs US$0.64 loss in FY 2022)
Simply Wall St.  ·  03-01
Lipella Pharmaceuticals Full Year 2023 Earnings: US$0.77 loss per share (vs US$0.64 loss in FY 2022)
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
GlobeNewswire  ·  02-20
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
BRIEF-Lipella Pharmaceuticals Inc Files For Mixed Shelf Of Up To $50 Million - SEC Filing
Reuters  ·  02-02
BRIEF-Lipella Pharmaceuticals Inc Files For Mixed Shelf Of Up To $50 Million - SEC Filing
BRIEF-Lipella Pharmaceuticals Marks Successful First Year With Strategic Progress And Key Milestones Accomplished
Reuters  ·  2023-12-20
BRIEF-Lipella Pharmaceuticals Marks Successful First Year With Strategic Progress And Key Milestones Accomplished
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished
GlobeNewswire  ·  2023-12-20
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished

Introduction

Company Name.
Lipella Pharmaceuticals Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Issue price:
--